Recent advances in monoclonal antibody-based therapeutics
10.16438/j.0513-4870.2017-0398
- VernacularTitle:单克隆抗体药物研究进展
- Author:
Chen-xi ZHAO
1
;
Zhuo-wei HU
1
;
Bing CUI
1
Author Information
1. State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
- Publication Type:REVIEWS
- Keywords:
biologics;
monoclonal antibody;
antibody-drug conjugate;
immunotherapy;
immune checkpoint
- From:
Acta Pharmaceutica Sinica
2017;52(6):837-847
- CountryChina
- Language:Chinese
-
Abstract:
Over the past four decades, monoclonal antibodies (MAbs) have evolved from bioscience research tools to powerful biopharmaceutical MAbs products for multiple diseases treatment. More than 50 therapeutic MAbs have been approved by FDA, widely used in cancer, autoimmune diseases and other diseases in current market. This article reviews the current progress of MAbs development technology, key molecules for cancer-targeted therapy and immunotherapy, and emphasizes the importance of MAbs for disease diagnosis and treatment.
